Cargando…

Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution

Until recently, platinum-based chemotherapy has represented the benchmark for the treatment of extensive disease small-cell lung cancer (ED-SCLC). ED-SCLC patients are often diagnosed with poor performance status (PS ≥2) and/or compromised organ functions. In fact, up to 63% of ED-SCLC has extensive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Federico, Alessandro, Andrini, Elisa, Sisi, Monia, Nuvola, Giacomo, Lamberti, Giuseppe, Lenzi, Barbara, Nobili, Elisabetta, Gelsomino, Francesco, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911106/ https://www.ncbi.nlm.nih.gov/pubmed/33661187 http://dx.doi.org/10.1097/CAD.0000000000001057

Ejemplares similares

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
por: Andrini, Elisa, et al.
Publicado: (2022)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Peripheral nervous system adverse events associated with immune checkpoint inhibitors
por: Rossi, Simone, et al.
Publicado: (2023)

Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand
por: Tharavichitkul, Ekkasit, et al.
Publicado: (2016)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

An Update on Appendiceal Neuroendocrine Tumors
por: Andrini, Elisa, et al.
Publicado: (2023)

Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2016)

Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
por: Mollica, Veronica, et al.
Publicado: (2022)

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
por: De Giglio, Andrea, et al.
Publicado: (2022)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
por: Korst, A. E., et al.
Publicado: (1997)

Tumors of low malignant potential a single institution experience
por: Jbir, Ichraf, et al.
Publicado: (2019)

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
por: Bokemeyer, C, et al.
Publicado: (2004)

The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients.
por: Ghazal-Aswad, S., et al.
Publicado: (1996)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer
por: Wenzel, Alexander T., et al.
Publicado: (2022)

Multidisciplinary management of extensive intravenous leiomyomatosis: A coordinated effort of a single institution
por: Thannickal, Aneesa, et al.
Publicado: (2020)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin
por: Björn, Niclas, et al.
Publicado: (2020)

Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
por: Khodadad, Kian, et al.
Publicado: (2014)

Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors
por: Brighi, Nicole, et al.
Publicado: (2023)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
por: Evans, W. K., et al.
Publicado: (1988)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Efficacy of replacing actinomycin-D with carboplatin in Ewing sarcoma consolidation treatment: Single-center experience
por: Özkan, Ayşe, et al.
Publicado: (2022)

Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
por: Ricco, Gianluca, et al.
Publicado: (2021)

Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort
por: Cobert, Julien, et al.
Publicado: (2009)

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience
por: Lee, Young-Jae, et al.
Publicado: (2017)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Epipericardial fat necrosis: increasing the rate of diagnosis by disseminating knowledge within a single institution
por: Giassi, Karina de Souza, et al.
Publicado: (2018)

Melanoma in the elderly patient: a single institution retrospective analysis
por: Desiato, Vincenzo, et al.
Publicado: (2013)

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

The treatment of extensive scalp lesions using coplanar and non-coplanar photon IMRT: a single institution experience
por: Ostheimer, Christian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_frd78pjrpfg033me0p0nvspg7n